` LSTA (Lisata Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

LSTA
vs
S&P 500

Over the past 12 months, LSTA has underperformed S&P 500, delivering a return of -46% compared to the S&P 500's +19% growth.

Stocks Performance
LSTA vs S&P 500

Loading
LSTA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LSTA vs S&P 500

Performance Gap Between LSTA and GSPC
HIDDEN
Show

Performance By Year
LSTA vs S&P 500

Loading
LSTA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Lisata Therapeutics Inc vs Peers

S&P 500
LSTA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Lisata Therapeutics Inc
Glance View

Market Cap
17.2m USD
Industry
Biotechnology

Lisata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The firm focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

LSTA Intrinsic Value
HIDDEN
Show
Back to Top